B. Metzler Seel. Sohn & Co. Ag Kymera Therapeutics, Inc. Transaction History
B. Metzler Seel. Sohn & Co. Ag
- $10 Billion
- Q3 2024
Shares
1 transactions
Others Institutions Holding KYMR
# of Institutions
181Shares Held
64.3MCall Options Held
50.6KPut Options Held
81.7K-
Price T Rowe Associates Inc Baltimore, MD6.65MShares$256 Million0.04% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$231 Million3.04% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$199 Million7.77% of portfolio
-
Atlas Venture Life Science Advisors, LLC4.9MShares$188 Million28.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.75MShares$183 Million0.0% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.11B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...